Skip to Main Content

3,017

Views

10

CrossRef citations to date

0

Altmetric

Original Articles

Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation–positive acute myeloid leukemia: the RADIUS-X expanded access program

Gail J. Roboza Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USACorrespondence[email protected]
View further author information

,

Stephen A. Stricklandb Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

https://orcid.org/0000-0002-6861-2041 View further author information

,

Mark R. Litzowc Mayo Clinic, Rochester, MN, USA

https://orcid.org/0000-0002-9816-6302 View further author information

,

Andrew Dalovisiod Ochsner Medical Center, New Orleans, LA, USAView further author information

,

Alexander E. Perle University of Pennsylvania, Philadelphia, PA, USA

https://orcid.org/0000-0002-1463-2231 View further author information

,

Gaetano Bonifaciof Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information

,

Kelly Hainesf Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information

,

Alysha Barberaf Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information

,

Das Purkayasthaf Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information

&

Kendra Sweetg Moffitt Cancer Center, Tampa, FL, USAView further author information